Melius Pharma is a Swedish company founded in 2021 focused on the development of new treatments for interstitial lung diseases.
The company’s lead project for chronic cough in idiopathic pulmonary fibrosis is set to enter a Phase IIa clinical proof of concept study. Chronic cough is a serious symptom in idiopathic pulmonary fibrosis that severely affects the quality of life in patients suffering from this disease. Median survival for patients after diagnosis is 3–5 years with current treatments according to the company.
Melius Pharma says its drug candidate is a new chemical entity benefiting from more than 20 years of safety data in man as well as efficacy data from both clinical and preclinical cough studies.
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies generative protein design to rapidly …
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness and direct the power of …
The biotech sector continues to see a strong flow of new venture capital deals, with a flurry of new announcements this week. We saw a diverse set of companies—ranging from …
THRONCAT is a new startup that aims to transform the field of protein analysis and mRNA therapeutics safety. THRONCAT began with a mission to make protein analysis more accessible and …
